Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).
Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient stratification for targeted therapy. It integrates cutting-edge evidence on standardized detection-including immunohistochemistry, in situ hybridization, and liquid biopsy-to overcome spatial-temporal heterogeneity. Recent progress in the use of HER2-targeted agents, including monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, and bispecific antibodies, is systematically reviewed and presented to inform evidence-based clinical practice. These updates aim to optimize personalized HER2-targeted therapy and improve outcomes in GC/GEJC patients.
Authors
Zhang Zhang, Wang Wang, Cai Cai, Wang Wang, Xie Xie, Ying Ying, Sheng Sheng, Fan Fan, Qu Qu, Wang Wang, Peng Peng, Ying Ying, Qiu Qiu, Liu Liu, Liu Liu, Lin Lin, Yao Yao, Li Li, Guan Guan, Xu Xu, Li Li, Bu Bu, Shen Shen
View on Pubmed